Regarding GC, better patient selection, including the selection of both positive (by HER2 copy numbers and/or d16HER2) and negative (by excluding tumors with co-existing oncogenic drivers)11 patients, could lead to a reassessment of the role of BC blockbuster drugs that failed in this disease, such as dual blockade with trastuzumab plus pertuzumab, TD-M1 and lapatinib, in highly HER2-addicted GC patients31–33. The gene discussed is ERBB2; the disease is gastric cancer.